Details
Stereochemistry | ACHIRAL |
Molecular Formula | C26H37NO8S2.ClH.H2O |
Molecular Weight | 610.18 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.Cl.COC1=CC=C(CCN(C)CCCC3(C2=CC(OC)=C(OC)C=C2)S(=O)(=O)CCCS3(=O)=O)C=C1OC
InChI
InChIKey=QRLOEYBBNMCMIM-UHFFFAOYSA-N
InChI=1S/C26H37NO8S2.ClH.H2O/c1-27(15-12-20-8-10-22(32-2)24(18-20)34-4)14-6-13-26(36(28,29)16-7-17-37(26,30)31)21-9-11-23(33-3)25(19-21)35-5;;/h8-11,18-19H,6-7,12-17H2,1-5H3;1H;1H2
Tiapamil (also known as Ro 11-1781) is a dithiane derivative patented by Hoffmann-La Roche, F., und Co., A.-G. as calcium-channel antagonist useful for myocardial infarction treatment. Tiapamil, like verapamil, inhibited in a concentration-dependent manner Ca2+-induced contractions in isolated, K+-depolarized preparations of rat renal artery, dog coronary artery and rabbit main pulmonary artery. The inhibitory effects of Tiapamil can be overcome by raising the Ca2+ concentration of the bath fluid. In the rabbit main pulmonary artery, Tiapamil reduces 45Ca influx into the K+-depolarized vascular smooth muscle cells. Tiapamil inhibits the slow potentials in partially depolarized guinea-pig papillary muscles. Tiapamil decreases contractile force in isolated guinea-pig atria and papillary muscles, as well as in isolated cat hearts. Tiapamil also reduces heart rate and increases coronary flow in these preparations. Tiapamil doubled coronary artery blood flow in the coronary sinus blood without producing major changes in blood pressure and heart rate in anesthetized dogs. Tiapamil did not affect contractions of isolated guinea-pig ileum, rat stomach strips or rat vas deferens in response to various stimulants. Tiapamil have no major effects on renal water and electrolyte excretion, on autonomic nerves and receptors, on pain perception and on the central nervous system. Acute, subacute, and chronic toxicity studies demonstrate low toxicity for Tiapamil with no tendency for accumulation. In clinical trials, Tiapamil effectively lowers systolic and diastolic blood pressure, but have no effects on heart rate
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Tiapride in levodopa-induced involuntary movements. | 1979 Apr |
|
[Cases of abnormal movements]. | 1979 Jan 8-15 |
|
Neuroleptic-induced acute dyskinesias in rhesus monkeys. | 1981 |
|
[Clinical trial of tiapride in patients with dyskinesia (author's transl)]. | 1982 Mar 25 |
|
Abnormal involuntary movements: a study of dopaminergic receptor interaction. | 1983 |
|
[Short-term obstetrical anesthesia. Study of the tiapride-ketamine combination]. | 1984 Jan |
|
Recurrent neuroleptic malignant syndrome due to tiapride and haloperidol: the possible role of D-2 dopamine receptors. | 1984 Nov |
|
[Long-term evaluation of tiapride in patients with various forms of dyskinesia]. | 1985 Oct |
|
A comparison of nine calcium ion antagonists and propranolol: exercise tolerance, heart rate and ST-segment changes in patients with chronic stable angina pectoris. | 1987 |
|
Comparative effects of prolonged therapy with four calcium ion antagonists (diltiazem, nicardipine, tiapamil and verapamil) in patients with chronic stable angina pectoris. | 1987 |
|
Comparison of the in-vitro receptor selectivity of substituted benzamide drugs for brain neurotransmitter receptors. | 1988 Jun |
|
The initial hemodynamic response to newer antihypertensive agents at rest and during exercise: review of visacor, doxazosin, nisoldipine, tiapamil, perindoprilat, pinacidil, dilevalol, and carvedilol. | 1990 Aug |
|
Prediction of catalepsies induced by amiodarone, aprindine and procaine: similarity in conformation of diethylaminoethyl side chain. | 1998 Nov |
|
Successful therapy of tardive dyskinesia in a 71-year-old woman with a combination of tetrabenazine, olanzapine and tiapride. | 2003 Mar |
|
Weak inhibitors protect cholinesterases from stronger inhibitors (dichlorvos): in vitro effect of tiapride. | 2005 Mar-Apr |
|
Weak inhibitors protect cholinesterases from strong inhibitors (paraoxon): in vitro effect of tiapride. | 2005 Nov-Dec |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2026464
150-300 mg/day or 450-600 mg/day for 5 weeks
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C333
Created by
admin on Fri Dec 15 15:11:17 GMT 2023 , Edited by admin on Fri Dec 15 15:11:17 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
87434-83-1
Created by
admin on Fri Dec 15 15:11:17 GMT 2023 , Edited by admin on Fri Dec 15 15:11:17 GMT 2023
|
PRIMARY | |||
|
V824N2T753
Created by
admin on Fri Dec 15 15:11:17 GMT 2023 , Edited by admin on Fri Dec 15 15:11:17 GMT 2023
|
PRIMARY | |||
|
CHEMBL125737
Created by
admin on Fri Dec 15 15:11:17 GMT 2023 , Edited by admin on Fri Dec 15 15:11:17 GMT 2023
|
PRIMARY | |||
|
C152601
Created by
admin on Fri Dec 15 15:11:17 GMT 2023 , Edited by admin on Fri Dec 15 15:11:17 GMT 2023
|
PRIMARY | |||
|
23621171
Created by
admin on Fri Dec 15 15:11:17 GMT 2023 , Edited by admin on Fri Dec 15 15:11:17 GMT 2023
|
PRIMARY | |||
|
D013976
Created by
admin on Fri Dec 15 15:11:17 GMT 2023 , Edited by admin on Fri Dec 15 15:11:17 GMT 2023
|
PRIMARY | |||
|
W-14
Created by
admin on Fri Dec 15 15:11:17 GMT 2023 , Edited by admin on Fri Dec 15 15:11:17 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD